Prime Medicine to Present at Jefferies Global Healthcare Conference
Rhea-AI Summary
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET in New York.
A live audio webcast and a 90-day replay will be available in the News & Events section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – PRME
In the May 28 session, PRME gained 3.03%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Negative | -8.7% | Reported Q1 2026 net loss and spending levels with runway into 2027. |
| Apr 16 | CFO appointment | Positive | -3.2% | Named new CFO with over 20 years of biotech and banking experience. |
| Mar 03 | FY 2025 earnings | Negative | -9.2% | Full-year 2025 results showed substantial net loss and high R&D spend. |
| Feb 25 | Investor conferences | Positive | +7.8% | Announced participation in three early March investor conferences with webcasts. |
| Jan 07 | JPM conference | Positive | +9.2% | Planned corporate overview at J.P. Morgan Healthcare Conference with 90-day replay. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has often sold off on financial updates but reacted positively to conference and investor-relations events.
Over the last six months, Prime Medicine has combined financial updates with growing investor outreach. Earnings reports on Mar 3, 2026 and May 7, 2026 highlighted substantial R&D spend and net losses, with shares falling after both releases. In contrast, participation in investor conferences on Jan 7 and Feb 25, 2026 coincided with positive price reactions. Today's Jefferies conference appearance continues that outreach pattern without adding new financial or clinical data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 12:50 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
